Table 5.
Weibull survival model with random effects in 2131 children on antiretroviral therapy (ART).
| Univariate analysis | Multivariate analysis | |||||
|---|---|---|---|---|---|---|
| HR* | CI (95%)** | P | aHR | CI (95%)** | P | |
| Sex | ||||||
| Boys | 1 | - | - | 1 | - | - |
| Girls | 1.0 | 0.8-1.3 | 0.72 | 1.0 | 0.8-1.2 | 0.78 |
| Age at ART initiation | ||||||
| 10 years and plus | 1 | - | - | 1 | - | - |
| [5-10] years | 0.9 | 0.6-1.2 | 0.32 | 0.9 | 0.7-1.3 | 0.56 |
| [3-5] years | 0.8 | 0.5-1.2 | 0.22 | 0.9 | 0.6-1.3 | 0.52 |
| [1-3] years | 1.3 | 0.9-1.8 | 0.10 | 1.1 | 0.8-1.6 | 0.34 |
| < 12 months | 1.4 | 0.6-2.9 | 0.36 | 1.1 | 0.5-2.4 | 0.66 |
| ART regimen at baseline | ||||||
| 2 NRTI+1 NNRTI | 1 | - | - | 1 | ||
| 2 NRTI+1 IP | 0.7 | 0.5-0.9 | 0.01 | 0.9 | 0.7-1.2 | 0.62 |
| Other | 0.6 | 0.2-1.5 | 0.24 | 1.0 | 0.4-2.5 | 0.98 |
| Clinical stage at ART initiation | ||||||
| A, B or I, II, III | 1 | - | - | 1 | - | - |
| AIDS or IV | 2.6 | 2.0-3.5 | < 0.01 | 2.3 | 1.7-3.0 | < 0.01 |
| Unknown | 1.3 | 0.8-2.1 | 0.21 | 1.4 | 0.9-2.3 | 0.15 |
| % CD4 at ART initiation | ||||||
| ≥ 15% | 1 | - | - | 1 | - | - |
| < 15% | 2.1 | 1.4.3.2 | < 0.01 | 1.9 | 1.3-2.9 | < 0.01 |
| Missing | 1.5 | 0.9-2.5 | 0.07 | 1.7 | 1.1-2.8 | 0.03 |
| Year of ART initiation | ||||||
| ≤ 2004 | 1 | - | - | 1 | - | - |
| 2005 | 2.0 | 1.5-2.7 | < 0.01 | 1.7 | 1.3-2.4 | < 0.01 |
| ≥ 2006 | 3.5 | 2.6-4.6 | < 0.01 | 3.0 | 2.2-4.0 | < 0.01 |
| Cotrimoxazole status at ART initiation | ||||||
| No | 1 | - | - | 1 | - | - |
| Yes | 1.2 | 0.7-1.8 | 0.43 | 0.9 | 0.6-1.4 | 0.63 |
| Missing | 0.6 | 0.2-1.8 | 0.32 | 0.4 | 0.1-1.5 | 0.16 |
IeDEA paediatric West Africa database (pWADA), 2000-2007. Loss-to-program analysis.
*HR = Hazard Ratio, **95% CI = 95% Confidence Interval, aHR = adjusted Hazard Ratio
Heterogeneity between cohort, p = 0.14